Purpose of RELIANCE:
Both roflumilast and azithromycin have been shown to reduce the risk of COPD exacerbations compared to placebo. However, there has not been a head-to-head comparison of these two FDA-approved medications. RELIANCE is intended to support hospital efforts to reduce the risk of all-cause hospitalization and premature deaths in individuals with COPD.
RELIANCE is Seeking Community-Based Hospitalists:
Hospitalists are critical in the development of post-discharge care plans and medications used by people with COPD. We found from preliminary work that identification of people with COPD while they are hospitalized is an efficient recruitment method for RELIANCE.
Benefits and Compensation:
- $500/year honorarium for being a community partner (paid after registration) plus $2,000 per patient enrolled.
- Option to participate in clinical roundtables with COPD thought leaders.
- Contribute topic ideas for future grant proposals or publications related to hospitalist care.
- Community Partners will not be investigators / authors, but will be acknowledged in the RELIANCE publication.
Please reach out to Tiffany.Lee@ucsf.edu if you are interested in participating and would like more information about RELIANCE.